Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort study.
Barth DA, Moik F, Steinlechner S, Posch F, Mayer MC, Sandner AM, Berton F, Schlintl V, Koch L, John N, Wurm R, Pichler M, Bauernhofer T, Reimann P, Wohlkönig C, Richtig E, Winder T, Preusser M, Jost PJ, Ay C, Gerger A, Terbuch A, Riedl JM. Barth DA, et al. J Immunother Cancer. 2023 Dec 14;11(12):e007765. doi: 10.1136/jitc-2023-007765. J Immunother Cancer. 2023. PMID: 38097343 Free PMC article.
C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study.
Riedl JM, Barth DA, Brueckl WM, Zeitler G, Foris V, Mollnar S, Stotz M, Rossmann CH, Terbuch A, Balic M, Niedrist T, Bertsch T, Stoeger H, Pichler M, Olschewski H, Absenger G, Ficker JH, Gerger A, Posch F. Riedl JM, et al. Among authors: barth da. Cancers (Basel). 2020 Aug 17;12(8):2319. doi: 10.3390/cancers12082319. Cancers (Basel). 2020. PMID: 32824580 Free PMC article.
Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
Riedl JM, Posch F, Horvath L, Gantschnigg A, Renneberg F, Schwarzenbacher E, Moik F, Barth DA, Rossmann CH, Stotz M, Schaberl-Moser R, Pichler M, Stöger H, Greil R, Djanani A, Schlick K, Gerger A. Riedl JM, et al. Among authors: barth da. Eur J Cancer. 2021 Jul;151:3-13. doi: 10.1016/j.ejca.2021.03.040. Epub 2021 May 2. Eur J Cancer. 2021. PMID: 33951545 Free article.
Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan-cancer study.
Barth DA, Stanzer S, Spiegelberg J, Bauernhofer T, Absenger G, Posch F, Lipp R, Halm M, Szkandera J, Balic M, Gerger A, Smolle MA, Hutterer GC, Klec C, Jost PJ, Kargl J, Stradner M, Pichler M. Barth DA, et al. Cancer Med. 2022 Aug;11(16):3074-3083. doi: 10.1002/cam4.4675. Epub 2022 Mar 16. Cancer Med. 2022. PMID: 35297215 Free PMC article.
Patterns of Peripheral Blood B-Cell Subtypes Are Associated With Treatment Response in Patients Treated With Immune Checkpoint Inhibitors: A Prospective Longitudinal Pan-Cancer Study.
Barth DA, Stanzer S, Spiegelberg JA, Bauernhofer T, Absenger G, Szkandera J, Gerger A, Smolle MA, Hutterer GC, Ahyai SA, Madl T, Posch F, Riedl JM, Klec C, Jost PJ, Kargl J, Stradner MH, Pichler M. Barth DA, et al. Front Immunol. 2022 Apr 1;13:840207. doi: 10.3389/fimmu.2022.840207. eCollection 2022. Front Immunol. 2022. PMID: 35432362 Free PMC article.
Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel.
Riedl JM, Schwarzenbacher E, Moik F, Horvath L, Gantschnigg A, Renneberg F, Posch F, Barth DA, Stotz M, Pichler M, Hatzl S, Fandler-Höfler S, Gressenberger P, Gary T, Jost PJ, Greil R, Ay C, Djanani A, Gerger A, Schlick K. Riedl JM, et al. Among authors: barth da. Thromb Haemost. 2022 Apr;122(4):633-645. doi: 10.1055/a-1548-4847. Epub 2021 Aug 24. Thromb Haemost. 2022. PMID: 34255340
34 results